Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL - Targeted Oncology

Retrieved on: 2024-06-10 21:22:27

Tags for this article:

Click the tags to see associated articles and topics

Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL - Targeted Oncology. View article details on hiswai:

Excerpt

Atrial fibrillation/atrial flutter with zanubrutinib of any grade was 6.8%, grade 3 or higher at 3.1% compared with 16.4% and 4.9% with ibrutinib ...

Article found on: www.targetedonc.com